T.R. Jeffry Evans

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

Medicine, Oncology, Pharmacology +12

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Colin W. Steele, Saadia A. Karim, Joshua D.G. Leach et al. · Cancer Cell · 2016 · 838 citations · Full text

Medicine, Cancer Biology, Oncology +17

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

Jennifer P. Morton, Paul Timpson, Saadia A. Karim et al. · Proceedings of the National Academy of Sciences · 2009 · 679 citations · Full text

Medicine, Molecular Biology, Oncology +16

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans et al. · Journal of Clinical Oncology · 2014 · 577 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Bryan W. Miller, Jennifer P. Morton, Mark Pinese et al. · EMBO Molecular Medicine · 2015 · 266 citations · Full text

Medicine, Oncology, Pharmacology +17